YAP silencing is able to enhance sensitivity to vemurafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) in a variety of tumor cells carrying the BRAF V600E mutant, without affecting vehicle-treated tumors. Here, MAP2K7 is linked to neoplasm.